- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05030246
Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer
A Phase Ⅱ, Single-arm Study to Evaluate the Efficacy and Safety of Surufatinib Combined With Toripalimab in Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Studietype
Registrering (Forventet)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Lin Shen, MD
- Telefonnummer: 86-10-88196561
- E-post: linshenpku@163.com
Studiesteder
-
-
Beijing
-
Beijing, Beijing, Kina, 100142
- Rekruttering
- Beijing Cancer Hospital
-
Ta kontakt med:
- Lin Shen, MD
- Telefonnummer: 86-10-88196561
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Histologically or cytologically confirmed advanced peritoneal metastatic carcinoma of gastrointestinal or primary peritoneal cancer
- Failed after standard treatment
- Have evaluable lesions, including those that are not measurable
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
- Adequately understand the study and voluntarily sign the Informed Consent Form;
- ≥18 years old;
- Lab tests within 7 days before first dose:
1) Absolute neutrophil count (ANC) ≥1.5×109/L, platelet count ≥100×109/L, and hemoglobin ≥100g/L; 2) Serum total bilirubin ≤1.5 times the upper limit of normal (ULN); 3) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels ≤2.5 times the ULN; 4) Patients without anticoagulant therapy: International Normalized Ratio (INR) ≤1.5 ULN and activated partial thromboplastin time (APTT) ≤1.5 ULN. If patients received anticoagulant therapy: INR ≤2 ULN and APTT was within the normal range 14 days before treatment; 5) Serum total bilirubin <1.5 times the upper limit of normal (ULN); 6) Urine protein < 2+; if ≥2+, 24-hour urine protein <1 g; 8. Male or females patients with reproductive potential must agree to use an effective contraceptive method, for example, double-barrier device, condom, oral or injected birth control medication or intrauterine device, during the study and within 90 days after study treatment discontinuation. All female patients are considered to be fertile, unless the patient had natural menopause or artificial menopause or sterilization (such as hysterectomy, bilateral oophorectomy or ovarian irradiation).
Exclusion Criteria:
- Prior system treatment with antiPD1/PDL1/PDL2/CTLA-4 antibody or Sulfatinib;
- Previous intraperitoneal treatment with immunologic agents;
- Patients with digestive tract obstruction or uncontrolled active bleeding from the primary tumor;
- Patients with any active autoimmune disease or a documented history of autoimmune disease: Patients with hypothyroidism but receiving a stable dose of thyroid hormone replacement therapy were included in the study, and subjects with stable type 1 diabetes were able to control their blood sugar;
- Pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-associated pneumonia, severe impaired lung function, etc;
- Prior major surgery within past 4 weeks and had not fully recovered from previous surgery;
- Active bleeding or abnormal coagulation, Prone to bleeding or receiving thrombolytic or anticoagulant therapy;
- Hypertension that is not controlled by the drug, and is defined as: SBP≥140 mmHg and/or DBP≥90 mmHg;
- Prior antitumor therapy (including chemotherapy, immunotherapy, biological treatment, Targeted therapy, etc) , or have not recovered from toxicities since the last treatment;
- Pregnant or nursing;
- previously received allogeneic stem cell or parenchymal organ transplantation;
- Any significant clinical or laboratory abnormality that the investigator considers to influence the safety evaluators;
- History of uncorrected serum electrolyte disturbances such as potassium, calcium, or magnesium;
- Known human immunodeficiency virus (HIV) infection;
- Active hepatitis B virus (HBV) and hepatitis C virus (HCV) infected persons;
- A history of other malignancies within 5 years prior to inclusion, except for cervical carcinoma in situ, basal or squamous cell skin cancer, localized prostate cancer treated with radical surgery, and ductal carcinoma in situ treated with radical surgery;
- Prior treatment with corticosteroids (dose > 10 mg/day prednisone or other hormones) or other immunosuppressive agents within 2 weeks, nasal or inhalation in allowed (dose > 10 mg/day prednisone or other hormones);
- Severe, uncontrolled medical condition that would affect patients' compliance or obscure the interpretation of toxicity determination or adverse events, including active severe infection, uncontrolled diabetes, angiocardiopathy (heart failure > class II NYHA, LVEF <50%, myocardial infarction, unstable arrhythmia or unstable angina within past 6 months, cerebral infarction within past 3 months) or pulmonary disease ( interstitial pneumonia, obstructive pulmonary disease or symptomatic bronchospasm);
- History with tuberculosis who are receiving or have received anti-TB treatment within 1 year;
- Active infection;
- Receiving another experimental drug or participating in a clinical study for another therapeutic purpose within the first 28 days prior to treatment initiation;
- Any other disease, metabolic disorder, abnormal results of a physical examination or laboratory examination, and reasonably suspected disease or condition that may contraindication the use of the investigational drug, or affect the reliability of the study results, or place the patient at high risk for treatment complications, or affect patient compliance.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Surufatinib 250mg/Toripalimab 240mg
Surufatinib at a dose of 250mg Qd, with humanized anti-PD-1 monoclonal antibody(Toripalimab) injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
|
Surufatinib 250mg will be taken orally once daily continuously through a 21-day cycle of study treatment.
Toripalimab 240mg will be intravenously administered on Day 1 of each cycle.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Overall Survival (OS)
Tidsramme: From date of first dose of study drug until withdrawal of consent or death (up to approximately 1 year)
|
Duration from the date of initial treatment with Surufatinib plus toripalimab to the date of death due to any cause.
|
From date of first dose of study drug until withdrawal of consent or death (up to approximately 1 year)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Progression-free Survival (PFS)
Tidsramme: From date of first dose of study drug until disease progression, withdrawal of consent, death, new anti-cancer therapy (up to approximately 1 year)
|
A duration from the date of initial treatment with Surufatinib combined with Toripalimab to disease progression or death of any cause.
|
From date of first dose of study drug until disease progression, withdrawal of consent, death, new anti-cancer therapy (up to approximately 1 year)
|
adverse events
Tidsramme: 1 year
|
Adverse events assessments are computed and categorized according to the Common Toxicity Criteria of the National Cancer Institute, version 5.0
|
1 year
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2021-012-CH04 IIT-GI
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Primær peritoneal kreft
-
NORCE Norwegian Research Centre ASNorwegian Labour and Welfare AdministrationFullførtAll International Classification of Primary Care 2 DiagnosesNorge
-
University of CincinnatiFullførtFibromyalgi | Juvenil Primary Fibromyalgia Syndrome (JPFS)Forente stater
-
Chulalongkorn UniversityUkjentPeritoneal membransviktThailand
-
Shanghai Jiao Tong University School of MedicineHar ikke rekruttert ennåPeritoneal skleroseKina
-
Fundacion para la Investigacion Biomedica del Hospital...Fullført
-
Memorial Sloan Kettering Cancer CenterY-mAbs TherapeuticsRekrutteringPeritoneal karsinom | Peritoneal kreft | Desmoplastisk liten rundcellet svulstForente stater
-
University of IowaFullført
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Gateway for Cancer ResearchAktiv, ikke rekrutterendePrimær peritoneal kreft | Eggleder | Epitelial eggstokkForente stater
-
Association Francaise de ChirurgieFullførtKarsinomatose, peritonealFrankrike
-
M.D. Anderson Cancer CenterFullførtPeritoneal kreftForente stater
Kliniske studier på Surufatinib/Toripalimab
-
The Affiliated Hospital of Xuzhou Medical UniversityRekruttering
-
Hutchison Medipharma LimitedFullførtAvanserte solide svulsterKina
-
Fujian Cancer HospitalHar ikke rekruttert ennåNasofaryngealt karsinomKina
-
Fudan UniversityUkjentKreft i skjoldbruskkjertelenKina
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Har ikke rekruttert ennå
-
Zhejiang UniversityRekruttering
-
Sun Yat-sen UniversityRekrutteringSmåcellet lungekarsinomKina
-
Fudan UniversityHar ikke rekruttert ennåIntrahepatisk kolangiokarsinom
-
Qilu Hospital of Shandong UniversityThe Affiliated Hospital of Qingdao University; Shandong Provincial Hospital... og andre samarbeidspartnereHar ikke rekruttert ennåNevroendokrin svulst grad 3
-
Qilu Hospital of Shandong UniversityHar ikke rekruttert ennå